Investing.com - Can Fite Biopharma ADR reported on Thursday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Can Fite Biopharma ADR announced earnings per share of $-0.08 on revenue of $250K. Analysts polled by Investing.com anticipated EPS of $-0.0933 on revenue of $166.67K.
Can Fite Biopharma ADR shares are down 61% from the beginning of the year, still down 65.38% from its 52 week high of $2.60 set on December 20, 2021. They are under-performing the OMX Helsinki 25 which is down 13.84% from the start of the year.
Can Fite Biopharma ADR shares lost 0.83% in intra-day trade following the report.
Can Fite Biopharma ADR follows other major Healthcare sector earnings this month
Can Fite Biopharma ADR's report follows an earnings missed by Eli Lilly on August 4, who reported EPS of $1.25 on revenue of $6.49B, compared to forecasts EPS of $1.7 on revenue of $6.85B.
Pfizer had beat expectations on July 28 with second quarter EPS of $2.04 on revenue of $27.74B, compared to forecast for EPS of $1.72 on revenue of $25.49B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar